|
|
Incorporated in 1995, Bafna Pharmaceuticals Limited is engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The Company manufactures 126 formulations under various therapeutic segments, such as anti-infective, cholesterol lowering agents, analgesic and antipyretic, antihelmintics, appetite stimulants, cough and cold preparations, antiulcerants anti diabetic, and vitamins.
In 2006, Bafna has set up an 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. The unit has been WHO GMP certified and also ISO 9000 certified. The products manufactured in this factory caters to the markets of Srilanka, Ghana and Ukraine. Bafna was involved in the execution of contracts for the generic division of M/s. Croslands from the period 1994 to 2001. Bafna was awarded the WHO GMP certification during the year 1995. Presently around 57 products of the company are registered in Srilanka, 4 products in Ukraine, 1 product in Ghana. The company received the Best Supplier award from the Srilankan Government during 2005.
| Particulars | For the year/period ended (Rs. in lacs) | ||||
| 30-Jun-07 | 31-Mar-07 | 31-Mar-06 | 31-Mar-05 | 31-Mar-04 | |
| Total Income | 432.02 | 3861.96 | 2136.47 | 2662.65 | 1521.33 |
| Profit After Tax (PAT) | 49.70 | 104.23 | 92.27 | 89.81 | 44.51 |
The objects of the Issue are to achieve the benefits of listing on the Stock Exchanges & to raise capital:
1. To undertake Brand Building exercise in domestic & international markets;
2. To part finance the cost of obtaining MHRA approval for Grantlyon unit;
3. To set up a Research & Development unit at Grantlyon;
4. To repay high cost debt;
5. To meet the working capital requirement;
6. To meet expenses of the Issue in order to achieve the benefits of listing on the Stock Exchanges;
7. General corporate purposes.
| Bafna Pharmaceuticals IPO Date | May 27, 2008 to May 30, 2008 |
| Bafna Pharmaceuticals IPO Face Value | ₹10 per share |
| Bafna Pharmaceuticals IPO Price | ₹40 per share |
| Bafna Pharmaceuticals IPO Lot Size | |
| Issue Size | 6,400,000 shares of ₹10 (aggregating up to ₹25.60 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE |
| Listing Date | Friday, June 27, 2008 |
| BSE Script Code | 532989 |
| NSE Symbol | BAFNAPHARM |
| Listing In | B Group of Securities |
| ISIN | INE878I01014 |
| IPO Price | ₹40 per share |
| Face Value | ₹10 per share |
|
|
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited,
299 Thambu Chetty Street,
Chennai - 600001, Tamil Nadu, India.
Phone: + 91-44-25267517
Email: cs@bafnapharma.com
Website: http://www.bafnapharma.com
Cameo Corporate Services Limited
Phone: +91-44-28460390
Email: cameo@cameoindia.com
Website: https://ipo.cameoindia.com/
Bafna Pharmaceuticals IPO is a main-board IPO of 6,400,000 equity shares of the face value of ₹10 aggregating up to ₹25.60 Crores. The issue is priced at ₹40 per share. The minimum order quantity is .
The IPO opens on May 27, 2008, and closes on May 30, 2008.
Cameo Corporate Services Limited is the registrar for the IPO. The shares are proposed to be listed on BSE.
The Bafna Pharmaceuticals IPO opens on May 27, 2008 and closes on May 30, 2008.
Bafna Pharmaceuticals IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Bafna Pharmaceuticals IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Bafna Pharmaceuticals IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Bafna Pharmaceuticals IPO allotment status.
Useful Articles
30 days brokerage free trading
Free - Relationship Manager
Free - Classroom Training
